Skyrizi achieves consistent results in plaque psoriasis across racial, ethnic groups
Click Here to Manage Email Alerts
Key takeaways:
- Patients that were white, Black, Asian or “other” achieved similar efficacy results with Skyrizi.
- Similar proportions of patients who were vs. were not Hispanic or Latino also saw comparable efficacy outcomes.
NEW YORK — Skyrizi exhibited efficacy across racial and ethnic groups for the treatment of moderate to severe plaque psoriasis, according to a presentation at the Skin of Color Update 2023 meeting.
“When we think about moderate to severe psoriasis, we have a lot of biologic options for treatment,” Raj Chovatiya, MD, PhD, assistant professor of dermatology at Northwestern University Feinberg School of Medicine, told Healio. “And [Skyrizi (risankizumab, AbbVie)] is one of the most efficacious ones we have that has pretty infrequent dosing and really good short- and long-term efficacy.”
During his presentation, Chovatiya reviewed the efficacy findings of a post-hoc integrated analysis that pulled data from four phase 3 studies — UltiMMa-1, UltiMMa-2, IMMvent and IMMhance — to assess Skyrizi treatment outcomes in moderate to severe plaque psoriasis in patients with skin of color vs. white patients.
Among the racial groupings, the post-hoc analysis included 1,020 white patients, 49 Black patients, 216 Asian patients and 21 that identified as “other,” which included American Indian or Alaskan Native and Native Hawaiian or other Pacific Islander individuals. Among the ethnic groupings, the study included 156 Hispanic or Latino patients vs. 1,150 non-Hispanic or Latino patients.
Each patient received subcutaneous injections of Skyrizi 150 mg at weeks 0 and 4.
After 16 weeks, results showed that Skyrizi was similarly efficacious across racial groupings with 74.8%, 69.4%, 70.4% and 76.2% of white, Black, Asian and “other” patients achieving PASI 90, respectively.
A high percentage of patients also achieved sPGA 0 or 1, including 84.5% of white patients, 83.7% of Black patients, 84.7% of Asian patients and 90.5% of “other” patients.
Those of varying ethnicities also achieved similar results, with 75.6% and 73.7% of Hispanic and non-Hispanic patients achieving PASI 90, respectively, and 87.8% and 84.3% of Hispanic and non-Hispanic patients achieving sPGA 0 or 1.
“We often have questions about what’s happening in individuals that might be in non-white groups,” Chovatiya told Healio. “And what the data shows is that [Skyrizi] is actually equally efficacious across all these populations, suggesting that it’s going to be a great treatment choice across all types of diverse skin types.”
Reference:
- Alexis A, et al. Short-term efficacy and racial and ethnic diversity in risankizumab phase 3 clinical trials for treatment of moderate to severe plaque psoriasis. Presented at: American Academy of Dermatology Annual Meeting; March 17–21, 2023; New Orleans.